keyword
MENU ▼
Read by QxMD icon Read
search

SMOAD

keyword
https://www.readbyqxmd.com/read/21622617/assessment-of-veterinary-practitioners-in-the-british-isles-approaches-towards-the-management-of-canine-osteoarthritis
#1
COMPARATIVE STUDY
N J Bound, M J Upjohn, S Jackson, S J Baines
The aim of this questionnaire-based retrospective study was to ascertain veterinary practitioners in the British Isles' approaches to osteoarthritis in dogs. The Mann-Whitney U test, Kruskal-Wallis test and multiple ordinal logistic regression were used to compare demographic data with treatment options. Questionnaires were returned by 228 practitioners (a response rate of 22.8 per cent). The majority of responses were from males (70 per cent). Eighty-six per cent (188 of 220) of the respondents had graduated from veterinary schools in the UK and Ireland...
May 28, 2011: Veterinary Record
https://www.readbyqxmd.com/read/21466452/a-review-of-current-animal-models-of-osteoarthritis-pain
#2
REVIEW
Warren N D'Souza, Gordon Y Ng, Bradley D Youngblood, Wayne Tsuji, Sonya G Lehto
Osteoarthritis (OA) is a complex disease plagued by a significant unmet need for treatment. To date, no disease- modifying OA drugs (DMOADs) exist and the available symptom-modifying OA drugs (SMOADs) have limitations. Although a complete understanding of the mechanisms of OA pain in humans is lacking, animal models have helped provide insight into the multifaceted origin and manifestation of OA pain. Success in discovering new therapeutics will likely require reliance on good animal models. This review summarizes the animal models available for studying pain associated with OA...
October 2011: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/19816688/which-elements-are-involved-in-reversible-and-irreversible-cartilage-degradation-in-osteoarthritis
#3
REVIEW
Anne-Christine Bay-Jensen, Suzi Hoegh-Madsen, Erik Dam, Kim Henriksen, Bodil Cecillie Sondergaard, Philippe Pastoureau, Per Qvist, Morten A Karsdal
Osteoarthritis (OA) is a disease of the entire joint. Different treatment strategies for OA have been proposed and tested clinically without the desired efficacy. One reason for the scarcity of current chondroprotective agents may be the insufficient understanding of the patho-physiology of the joint and whether the joint damage is reversible or irreversible. In this review, we compile emerging data on cellular and pathological aspects of OA, and ask whether these data could give clue to when cartilage degradation is reversible and whether a point-of-no-return exists...
February 2010: Rheumatology International
https://www.readbyqxmd.com/read/11709113/joint-structure-modification-in-osteoarthritis-development-of-smoad-drugs
#4
REVIEW
J F Beary
Primary osteoarthritis (OA) is a polygenic disease associated with age and obesity. In the OA disease setting, abnormal bone anatomy and biomechanics can set off a tissue repair response (intertwined with a mild inflammatory state) that can be seen with the imaging tools of bone scintigraphy and magnetic resonance imaging. This report focuses on weight-bearing OA (knee and hip) and looks at initiating and disease expression events in the subchondral trabecular bone. Multiple drug development targets in soft tissue (cartilage) and hard tissue (bone) can be justified...
December 2001: Current Rheumatology Reports
https://www.readbyqxmd.com/read/10073500/the-pathobiology-of-osteoarthritis-and-the-rationale-for-the-use-of-pentosan-polysulfate-for-its-treatment
#5
REVIEW
P Ghosh
OBJECTIVES: Structure-modifying osteoarthritis (OA) drugs (SMOADs) may be defined as agents that reverse, retard, or stabilize the underlying pathology of OA, thereby providing symptomatic relief in the long-term. The objective of this review was to evaluate the literature on sodium pentosan polysulfate (NaPPS) and calcium pentosan polysulfate (CaPPS), with respect to the pathobiology of OA to ascertain whether these agents should be classified as SMOADs. METHODS: Published studies on NaPPS and CaPPS were selected on the basis of their relevance to the known pathobiology of OA, which also was reviewed...
February 1999: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/9429735/pharmacotherapy-and-osteoarthritis
#6
REVIEW
S J Brady, P Brooks, P Conaghan, L M Kenyon
Therapy for osteoarthritis (OA) is aimed at relieving symptoms and at maximizing function. Therapies can be considered as either symptom modifying OA drugs (SMOADs) or as disease modifying OA drugs (DMOADs). Currently available agents fall into the category of SMOADs. Analgesic medications, particularly paracetamol and capsaicin, have proven efficacy in OA and are recommended first line therapies. Non-steroidal anti-inflammatory drugs (NSAIDs) do appear to provide extra symptomatic benefit for some patients but have greater toxicity...
November 1997: Baillière's Clinical Rheumatology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"